Alluvi, previously BI 4744, presents a significant development in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates https://whitebookmarks.com/story22228654/alluvi-a-in-depth-examination-into-the-medication-s-prospects